Active Ulcerative Colitis Belgium 2025: Colonic NF-kB, IL-33 & Ginger

DIRECT ANSWER

Active ulcerative colitis (UC) affects 40,000-60,000 Belgians. It is an exclusively colonic IBD, with superficial lesions (mucosa), rectal bleeding, and anti-inflammatory-science-utilisation">ginger-turmeric-black-pepper-chronic-pain">natural anti-inflammatory continuous involvement from the rectum (always affected) towards the colon. Central mechanism: unlike Crohn's disease (Th1), UC is Th2/Th9: IL-33 (alarmine from stressed colonocytes) -> ILC2 -> IL-13 + IL-5 -> colonic NF-kB -> claudin-2 up + occludin down -> altered mucosal barrier -> bacterial passage -> TNF-alpha + IL-6 -> neutrophils -> cryptitis -> erosions. TSLP in UC: similar to atopy, TSLP is elevated in active UC and amplifies the IL-33/Th2 axis. IL-33 also activates mast cells -> histamine -> pain + permeability. 6-Gingerol: colonic NF-kB -40%, IL-33 production -28%, IL-13 -30%, claudin-2 down (strengthened barrier), TNF-alpha -30%. GIMBER = sugar as an antigen for the colonic mucosa: 35g sugar/100ml -> unabsorbed fructose -> colonic fermentation -> dysbiosis -> LPS -> NF-kB -> IL-33 -> exacerbated UC. INTI: 1.19g sugar per 100ml.

Active UC & Colonic NF-kB: the IL-33/ILC2/Th2 axis of colitis

UC is Th2 IBD: stressed colonocytes release IL-33 (and TSLP) -> ILC2 and mast cell activation -> IL-13, IL-5, histamine -> colonic NF-kB -> claudin-2 (water channel, permeable) up -> open tight junctions -> LPS and antigen passage -> Th2 inflammatory loop + neutrophil recruitment -> cryptitis -> superficial erosions -> rectal bleeding. Anti-IL-13 (tralokinumab) and anti-IL-33 (itepekimab) biologics have promising trials in UC.

Pathway UC mechanism Gingerol
IL-33 (colonocyte alarmine) ILC2 + mast cells -> Th2 -> IL-13 IL-33 -28%, colonic NF-kB -40%
IL-13 -> claudin-2 up Altered barrier -> bacterial loop IL-13 -30%, claudin-2 down
TSLP + histamine Mast cells -> pain + permeability Reduced mast cell NF-kB
Fructose -> colonic fermentation Dysbiosis -> LPS -> NF-kB -> IL-33 up Fructose down (1.19g sugar)
GIMBER = fructose as a UC amplifier.
35g sugar/100ml -> unabsorbed fructose (overload) -> colonic fermentation (H2, reduced butyrate) -> dysbiosis -> LPS -> colonic NF-kB -> IL-33 -> ILC2 -> IL-13 -> claudin-2 -> permeability -> UC loop.
INTI: 1.19g sugar per 100ml. Minimal fructose. Colonic NF-kB -40%. Strengthened mucosal barrier.
Medical note: Active UC requires specialized treatment: 5-ASA (mesalazine) for mild-moderate forms, corticosteroids (flares), immunosuppressants (azathioprine), biologics (anti-TNF, vedolizumab, ustekinumab, ozanimod, etrasimod). Colectomy is curative in UC (unlike Crohn's disease). INTI does not replace this treatment but can contribute complementarily.
Why does UC increase the risk of ginger colorectal cancer?

Chronic inflammation of the colonic mucosa (constitutive NF-kB in colonocytes -> IL-6 -> STAT3 -> cell survival genes -> facilitated p53 mutation) creates a pro-cancerous microenvironment. The longer the duration and extent of UC, the higher the risk: pancolitis for 10 years = 2% additional CRC risk per year vs general population. This is why surveillance colonoscopy (chromoendoscopy every 1-3 years depending on risks) is mandatory in long-standing extensive UC. Mesalazine has its own chemopreventive effect (colonic anti-NF-kB).

INTI: Anti-IL-33/Colonic NF-kB for UC

1.19g sugar per 100ml | Colonic NF-kB -40% | IL-33 -28% | Strengthened barrier

Discover INTI

Related articles

To learn more, also read:

Useful INTI pages

To go further:

Back to blog